{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T12:25:41Z","timestamp":1787142341532,"version":"build-2736575974"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.urolonc.2026.07.022","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T11:37:53Z","timestamp":1787139473000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Technical requirements and platform considerations for molecular residual disease in genitourinary tumors"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1853-9218","authenticated-orcid":false,"given":"Jong Taek","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2026.07.022_bib0001","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-med-041316-085721","article-title":"Circulating tumor DNA: measurement and clinical utility","volume":"69","author":"Donaldson","year":"2018","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0002","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41591-019-0561-9","article-title":"Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers","volume":"25","author":"Parikh","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0003","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1097\/MS9.0000000000002776","article-title":"Liquid biopsies for early detection and monitoring of cancer: advances, challenges, and future directions","volume":"87","author":"Qureshi","year":"2025","journal-title":"Ann Med Surg"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0004","article-title":"Advancements and applications of liquid biopsies in oncology: a narrative review","volume":"15","author":"Noor","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0005","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nrc3066","article-title":"Cell-free nucleic acids as biomarkers in cancer patients","volume":"11","author":"Schwarzenbach","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0006","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10555-016-9629-x","article-title":"Origins, structures, and functions of circulating DNA in oncology","volume":"35","author":"Thierry","year":"2016","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0007","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.csbj.2018.10.002","article-title":"Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management","volume":"16","author":"Elazezy","year":"2018","journal-title":"Comput Struct Biotechnol J"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0008","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0009","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1006162","article-title":"Fragment length of circulating tumor DNA","volume":"12","author":"Underhill","year":"2016","journal-title":"PLoS Genet"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0010","doi-asserted-by":"crossref","first-page":"351","DOI":"10.4143\/crt.2022.1026","article-title":"Clinical circulating tumor DNA testing for precision oncology","volume":"55","author":"Kim","year":"2023","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0011","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41576-018-0071-5","article-title":"Current and future perspectives of liquid biopsies in genomics-driven oncology","volume":"20","author":"Heitzer","year":"2019","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105109","article-title":"Circulating tumour DNA-based molecular residual disease detection in resectable cancers: a systematic review and meta-analysis","volume":"103","author":"Zheng","year":"2024","journal-title":"eBioMedicine"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0013","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231911732","article-title":"Cell-free DNA as a prognostic biomarker for monitoring muscle-invasive bladder cancer","volume":"23","author":"Carrasco","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.12.018","article-title":"ctDNA-guided immunotherapy following radical cystectomy for muscle-invasive bladder cancer: results from the TOMBOLA trial","author":"Dyrskj\u00f8t","year":"2026","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0015","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1200\/JCO.2025.43.16_suppl.4565","article-title":"Association of tumor-informed ctDNA-based molecular residual disease (MRD) with clinical outcomes for upper tract urothelial cancer (UTUC)","volume":"43","author":"Ayanambakkam","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0016","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa2511885","article-title":"ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer","volume":"393","author":"Powles","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0017","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.eururo.2024.01.002","article-title":"Ultrasensitive detection of circulating tumour DNA enriches for patients with a greater risk of recurrence of clinically localised prostate cancer","volume":"85","author":"Pope","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0018","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-020-00770-1","article-title":"Detection of ctDNA in plasma of patients with clinically localised prostate cancer is associated with rapid disease progression","volume":"12","author":"Lau","year":"2020","journal-title":"Genome Med"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0019","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41416-025-02985-8","article-title":"Prognostic significance of circulating tumor DNA alterations in advanced renal cell carcinoma from SCRUM-Japan MONSTAR-SCREEN: a nationwide genomic profiling project","volume":"133","author":"Kato","year":"2025","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0020","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.annonc.2023.06.001","article-title":"Fragmentomic analysis of circulating tumor DNA-targeted cancer panels","volume":"34","author":"Helzer","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0021","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/s41436-020-0801-x","article-title":"Plasma cell-free DNA variant analysis compared with methylated DNA analysis in renal cell carcinoma","volume":"22","author":"Lasseter","year":"2020","journal-title":"Genet Med"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0022","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1158\/2159-8290.CD-18-0825","article-title":"Detection and surveillance of bladder cancer using urine tumor DNA","volume":"9","author":"Dudley","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0023","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.eururo.2024.11.011","article-title":"Novel methods to assess tumor burden and minimal residual disease in genitourinary cancers","volume":"87","author":"Barata","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0024","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa2511885","article-title":"ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer","volume":"393","author":"Powles","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0026","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1111\/cas.15334","article-title":"Perioperative circulating tumor DNA enables the identification of patients with poor prognosis in upper tract urothelial carcinoma","volume":"113","author":"Nakano","year":"2022","journal-title":"Cancer Sci"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0027","unstructured":"Thermo Fisher Scientific\u2014US Oncomine cfNA assays for clinical oncology research 2026 Available from:https:\/\/www.thermofisher.com\/us\/en\/home\/life-science\/cancer-research\/cancer-genomics\/liquid-biopsy-cancer-research-applications\/oncomine-cell-free-dna-assays-liquid-biopsy-clinical-research.html"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0028","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2024.1423470","article-title":"From haystack to high precision: advanced sequencing methods to unraveling circulating tumor DNA mutations","volume":"11","author":"Silva","year":"2024","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2019.101951","article-title":"Whole exome sequencing of cell-free DNA: a systematic review and Bayesian individual patient data meta-analysis","volume":"83","author":"Bos","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0030","first-page":"201","article-title":"The changing face of circulating tumor DNA (ctDNA) profiling: factors that shape the landscape of methodologies, technologies, and commercialization","volume":"35","author":"Bronkhorst","year":"2023","journal-title":"Medizinische Genet Mitteilungsblatt des Berufsverbandes Medizinische Genet eV"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0031","series-title":"Enable CGP from ctDNA in blood plasma","year":"2026"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0032","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2018.4305","article-title":"Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer","volume":"5","author":"Aggarwal","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0033","series-title":"Guardant360\u00ae Liquid: #1 liquid biopsy for treatment selection","year":"2026"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0034","series-title":"Foundation medicine","year":"2026"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0035","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nm.3519","article-title":"An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage","volume":"20","author":"Newman","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0036","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252111439","article-title":"Evaluating bioinformatics processing of somatic variant detection in cfDNA using targeted sequencing with UMIs","volume":"25","author":"Lin","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0037","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaw0726","article-title":"RNA sequence analysis reveals macroscopic somatic clonal expansion across normal tissues","volume":"364","author":"Yizhak","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0038","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0039","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jmoldx.2023.09.004","article-title":"Recommendations for cell-free DNA assay validations: a joint consensus recommendation of the Association for Molecular Pathology and College of American Pathologists","volume":"25","author":"Lockwood","year":"2023","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0040","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-021-00898-8","article-title":"Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients","volume":"13","author":"Tsui","year":"2021","journal-title":"Genome Med"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0041","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/cas.16025","article-title":"Postoperative recurrence detection using individualized circulating tumor DNA in upper tract urothelial carcinoma","volume":"115","author":"Tamura","year":"2023","journal-title":"Cancer Sci"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0042","doi-asserted-by":"crossref","DOI":"10.3390\/ph14060596","article-title":"cfDNA sequencing: technological approaches and bioinformatic issues","volume":"14","author":"Bohers","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0043","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40139-019-00193-7","article-title":"Biospecimen science of blood for cfDNA genetic analyses","volume":"7","author":"Ammerlaan","year":"2019","journal-title":"Curr Pathobiol Rep"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0044","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.clinbiochem.2016.03.012","article-title":"Comparative analysis of circulating tumor DNA stability In K3EDTA, Streck, and CellSave blood collection tubes","volume":"49","author":"Kang","year":"2016","journal-title":"Clin Biochem"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2025.100301","article-title":"International society of liquid biopsy (ISLB) perspective on minimal requirements for ctDNA testing in solid tumors","volume":"8","author":"Fusco","year":"2025","journal-title":"J Liq Biopsy"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0046","series-title":"FASTQ 1000 genomes","year":"2026"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0047","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3390\/diseases13100312","article-title":"Real-world technical hurdles of ctDNA NGS analysis: lessons from clinical implementation","volume":"13","author":"Cabello-Aguilar","year":"2025","journal-title":"Diseases"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0048","unstructured":"GATK 2026. Available from: https:\/\/gatk.broadinstitute.org\/hc\/en-us"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0049","doi-asserted-by":"crossref","first-page":"D777","DOI":"10.1093\/nar\/gkw1121","article-title":"COSMIC: somatic cancer genetics at high-resolution","volume":"45","author":"Forbes","year":"2017","journal-title":"Nucl Acids Res"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00011","article-title":"OncoKB: a precision oncology knowledge base","author":"Chakravarty","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0051","series-title":"Clinical genome resource","year":"2026"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0052","unstructured":"gnomAD 2026 Available from: https:\/\/gnomad.broadinstitute.org\/"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0053","series-title":"Treatment by cancer type","year":"2026"},{"key":"10.1016\/j.urolonc.2026.07.022_bib0054","series-title":"Guidelines ESMO","year":"2026"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926006162?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926006162?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T11:38:02Z","timestamp":1787139482000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926006162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":53,"alternative-id":["S1078143926006162"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.07.022","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Technical requirements and platform considerations for molecular residual disease in genitourinary tumors","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.07.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}